PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
JANX vs. VKTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between JANX and VKTX is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

JANX vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Janux Therapeutics, Inc. (JANX) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%1,000.00%1,200.00%NovemberDecember2025FebruaryMarchApril
18.05%
293.75%
JANX
VKTX

Key characteristics

Sharpe Ratio

JANX:

-0.50

VKTX:

-0.78

Sortino Ratio

JANX:

-0.49

VKTX:

-1.22

Omega Ratio

JANX:

0.95

VKTX:

0.86

Calmar Ratio

JANX:

-0.64

VKTX:

-0.82

Martin Ratio

JANX:

-1.20

VKTX:

-1.57

Ulcer Index

JANX:

34.46%

VKTX:

41.20%

Daily Std Dev

JANX:

82.28%

VKTX:

83.49%

Max Drawdown

JANX:

-83.14%

VKTX:

-90.41%

Current Drawdown

JANX:

-55.58%

VKTX:

-74.67%

Fundamentals

Market Cap

JANX:

$1.75B

VKTX:

$2.69B

EPS

JANX:

-$1.28

VKTX:

-$1.01

PS Ratio

JANX:

165.74

VKTX:

0.00

PB Ratio

JANX:

1.72

VKTX:

3.05

Total Revenue (TTM)

JANX:

$9.34M

VKTX:

$0.00

Gross Profit (TTM)

JANX:

$8.83M

VKTX:

-$162.00K

EBITDA (TTM)

JANX:

-$77.16M

VKTX:

-$116.74M

Returns By Period

In the year-to-date period, JANX achieves a -44.55% return, which is significantly lower than VKTX's -40.51% return.


JANX

YTD

-44.55%

1M

-3.95%

6M

-40.66%

1Y

-39.22%

5Y*

N/A

10Y*

N/A

VKTX

YTD

-40.51%

1M

-20.39%

6M

-63.62%

1Y

-62.98%

5Y*

33.71%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

JANX vs. VKTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JANX
The Risk-Adjusted Performance Rank of JANX is 2424
Overall Rank
The Sharpe Ratio Rank of JANX is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of JANX is 2626
Sortino Ratio Rank
The Omega Ratio Rank of JANX is 2929
Omega Ratio Rank
The Calmar Ratio Rank of JANX is 1414
Calmar Ratio Rank
The Martin Ratio Rank of JANX is 2323
Martin Ratio Rank

VKTX
The Risk-Adjusted Performance Rank of VKTX is 1010
Overall Rank
The Sharpe Ratio Rank of VKTX is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of VKTX is 1111
Sortino Ratio Rank
The Omega Ratio Rank of VKTX is 1414
Omega Ratio Rank
The Calmar Ratio Rank of VKTX is 55
Calmar Ratio Rank
The Martin Ratio Rank of VKTX is 99
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

JANX vs. VKTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for JANX, currently valued at -0.50, compared to the broader market-2.00-1.000.001.002.003.00
JANX: -0.50
VKTX: -0.78
The chart of Sortino ratio for JANX, currently valued at -0.49, compared to the broader market-6.00-4.00-2.000.002.004.00
JANX: -0.49
VKTX: -1.22
The chart of Omega ratio for JANX, currently valued at 0.95, compared to the broader market0.501.001.502.00
JANX: 0.95
VKTX: 0.86
The chart of Calmar ratio for JANX, currently valued at -0.64, compared to the broader market0.001.002.003.004.00
JANX: -0.64
VKTX: -0.82
The chart of Martin ratio for JANX, currently valued at -1.20, compared to the broader market-5.000.005.0010.0015.0020.00
JANX: -1.20
VKTX: -1.57

The current JANX Sharpe Ratio is -0.50, which is higher than the VKTX Sharpe Ratio of -0.78. The chart below compares the historical Sharpe Ratios of JANX and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00NovemberDecember2025FebruaryMarchApril
-0.50
-0.78
JANX
VKTX

Dividends

JANX vs. VKTX - Dividend Comparison

Neither JANX nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

JANX vs. VKTX - Drawdown Comparison

The maximum JANX drawdown since its inception was -83.14%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for JANX and VKTX. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-55.58%
-74.67%
JANX
VKTX

Volatility

JANX vs. VKTX - Volatility Comparison

The current volatility for Janux Therapeutics, Inc. (JANX) is 21.21%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 27.86%. This indicates that JANX experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
21.21%
27.86%
JANX
VKTX

Financials

JANX vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Janux Therapeutics, Inc. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab